PRESTIGE BIOPHARMA
PRESTIGE BIOPHARMA IDC
PRESTIGE BIOLOGICS
Beyond technological discovery, expanding access to care for patients around the world
Innovative Drug
Development of First-in-Class therapeutics for unmet diseases
Biosimilar
Prominent Biosimilars pipelines for accelerating market access
Platform Technology
A drug delivery platform that enhances treatment convenience
Diagnostics
Diagnostics for Pancreatic cancer by detecting PAUF
Prestige Biopharma IDC Files Patent for Sustained-Release Subcutaneous Delivery Platform for High-Concentration Protein Therape
Prestige Biopharma IDC Files Patent for Sustained-Release Subcutaneous Delivery Platform for High-Concentration Protein Therapeutics
Prestige Biopharma IDC (CEO: Sang-Seok Koh), the R&D center of Prestige Biopharma, announced that it has filed a domestic patent application for a temperature-responsive hydrogel formulation designed to deliver high-concentration protein therapeutics with sustained release in the body.
The technology enables efficient delivery of various protein-based drugs while allowing prolonged release after subcutaneous administration.
In recent years, subcutaneous (SC) formulations have gained increasing attention in the global biopharmaceutical market due to their ability to improve both patient convenience and therapeutic efficiency. Many antibody therapeutics are being developed or converted into SC formulations because they can significantly reduce the need for hospital visits.
The newly filed patent represents Prestige Biopharma IDC’s entry into the next-generation drug delivery system (DDS) field
The patented temperature-responsive hydrogel formulation remains in liquid form during storage and prior to injection but rapidly transitions into a gel state after administration in the body. Once gelation occurs, the system enables sustained release of the therapeutic protein over an extended period.
This property allows for potentially longer dosing intervals compared with conventional subcutaneous formulations.
CEO Sang-Seok Koh stated that the patent filing marks an important step toward independently developing subcutaneous formulations that can enhance patient convenience and treatment efficiency.
He added that the company plans to validate the platform through nonclinical and clinical studies and expand its application to a wide range of protein therapeutics.
Through this platform, Prestige Biopharma IDC aims to strengthen its competitiveness in the global subcutaneous formulation market while contributing to improvements in patient quality of life.
Source: http://www.paxetv.com
Read Prestige news >>
